Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Q3 FY2022 Earnings Presentation

15 slides from Strides Pharma Science's earnings presentation, Feb 10, 2022

  1. Slide 1: Q3 and 9MFY22 Earnings

    Q3 and 9MFY22 Earnings February 10, 2022

  2. Slide 2: Highlights and lowlights for Q3FY22

    Highlights and lowlights for Q3FY22 Strides reports muted performance during Q3 FY22, course correction on track for full recovery in FY23 Gross margin compression in Q3 due to portfolio and business mix along with increase in raw material prices for certain products Drop in revenues and gross margi

  3. Slide 3: Management on business performance during Q3 FY22

    Management on business performance during Q3 FY22 In Q3FY22, while we have delivered an 8% sequential revenue growth for our business, operating leverage continues to be subdued. Revenues Mix Our US business has returned to growth after two quarters of decline, growing 13% QoQ to $38m in Q3FY22. We

  4. Slide 4: Financial performance in Q3 and 9M FY22 results

    Financial performance in Q3 and 9M FY22 results Q3FY22 Q2FY22 Q3FY21 QoQ% YoY% 9MFY22 9MFY21 YoY % REVENUES ₹7,968m ₹7,360m ₹8,375m 8% - 5% ₹22,247m ₹24,193m - 8% ₹3,957m ₹4,113m ₹4,869m -4% - 19% ₹11,499m ₹14,580m - 21% GROSS MARGINS 49.7% 55.9% 58.1% -620 bps - 840 bps 51.7% 60.3% - 860 bps ₹40m ₹

  5. Slide 5: Performance Overview – Q3 and 9M FY22

    Performance Overview – Q3 and 9M FY22 Key Updates Regulated Markets Regulated Markets US Market Q3FY22 Q2FY22 Q3FY21 QoQ% YoY% 9MFY22 9MFY21 YoY% • US revenues at $38m for Q3FY22 up from $34m in Q2FY22, US contributed 36% of consolidated revenues in Q3FY22 US 2,831 2,502 3,876 13% -27% 8,349 11,661

  6. Slide 6: Business Highlights

    Business Highlights

  7. Slide 7: US business returns to growth, momentum to pick up in coming quarters

    US business returns to growth, momentum to pick up in coming quarters US Revenues - Quarterly Trend (₹/$M) Business Updates Significant price • Revenues from the US for Q3FY22 stood at ₹2,831 ($38m), up 13% QoQ, erosion impacts representing 36% of consolidated revenues for Q3FY22 55 58 50 50 54 • In

  8. Slide 8: Steady performance in the other regulated markets

    Steady performance in the other regulated markets Other Regulated Markets Revenues - Quarterly Trend (₹/$M) Business Updates Covid related supply • Revenues from other regulated markets for Q3FY22 stood at ₹2,990m disruptions ($40m), up 6% QoQ 35 40 37 38 40 • Other regulated markets represented 37%

  9. Slide 9: Emerging markets business continues its growth momentum

    Emerging markets business continues its growth momentum with a 41% YoY growth Emerging Market Revenues - Quarterly Trend (₹/$M) Business Updates • Revenues from emerging markets for Q3FY22 stood at ₹2,148m ($29m), up 6% QoQ and up 41% YoY 29 29 28 • Emerging markets business represented 27% of conso

  10. Slide 10: Financial Performance

    Financial Performance

  11. Slide 11: Key P&L Highlights – Q3 and 9MFY22

    Key P&L Highlights – Q3 and 9MFY22 Income statement (₹m) Particulars Q3 FY22 Q2 FY22 Q3 FY21 QoQ YoY 9M FY22 9M FY21 YoY Revenues 7,968 7,360 8,375 8% -5% 22,247 24,193 -8% EBITDA 40 10 1,661 -418 4,895 -109% EBITDA % 0.5% 0.1% 19.8% -1.9% 20.2% Adj PAT1,2 -870 -847 Adj EPS1,2 -9.7 -9.4 Reconciliati

  12. Slide 12: Net debt and Investments

    Net debt and Investments Pharma Net Debt Investments in CHC & Biotech Total Net Debt As at September 2021 As at September 2021 As at September 2021 ₹ 9,301m ₹ 6,937m ₹ 16,238m As at December 2021 As at December 2021 As at December 2021 ₹ 11,672m ₹ 6,937m ₹ 18,609m Change over September 2021 Change o

  13. Slide 13: Fund-raising update

    Fund-raising update • The Board of Directors at the meeting held today, approved a proposal for fund raising by issue of convertible warrants through preferential issue on a private placement basis to the family office of the Promoters • The Board of Directors have approved issue of up to 4 million

  14. Slide 14: Q3 and 9MFY22 Earnings Call invitation

    Strides Pharma Science Ltd – Q3 and 9MFY22 Earnings Call Pre-register and join without operator CLICK HERE invites you to interact with the senior management on Q3 and 9MFY22 Join through an operator using dial in Thursday, 10th February, 2022 numbers 3:00pm IST / 09:30am GMT / 04:30am EST / 05:30pm

  15. Slide 15: Thank You

    Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India Tel.: +91 22 2789 2924/2789 3199 Email: corpcomm@strides.com Website: www.strides.com CIN: L24230MH1990PLC057062 CORPORATE OFFICE Bannerghatta Road, Be

Strides Pharma Science — Q3 FY2022 Earnings Presentation on 6ix